|
Post by mnholdem on Jun 21, 2016 17:16:22 GMT -5
MannKind can assist the patient with co-pay or they can provide rebates to the BPM. Either one works, but getting a Preferred tier rating for Afrezza is the better and primary objective. Getting coverage that is equivalent to RAA would also be seen as a short-term victory until the label can be changed to a new classification Ultra- or Super-Rapid. Then Afrezza has a much better chance of getting a Preferred tier coverage with low co-pays.
|
|
|
Post by brotherm1 on Jun 21, 2016 19:31:44 GMT -5
Thank you Agedhippie and Mnholdem and Iam2sekc4u2002. I was reading the Formulary Coverage tracking sectiion on this site for Afrezza. Great stuff. I see you, mnholdem, a while back started posting the formulary coverage tracking data chart for Afrezza and the data format from the formulary checker website changed around February of this year making it difficult to tell how much coverage increased over time for Aftezza. I thought - not certain - I saw a link somewhere on the formulary tracking section that someone posted a link to view the history/chart of insurance coverage for Afrezza and coverage for it compared to other insulins. I'll reread the thread and/or search for such a site and pass on what I find if anything. I've got a lot of beans in this one and work everyday to try to stay on top of it. Again, this is a great board, many thanks to the administrators and posters.
|
|